SH
Therapeutic Areas
Vertex Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Vanzacaftor/Tezacaftor/Deutivacaftor | Cystic Fibrosis | Phase 3 |
| Exagamglogene Autotemcel (CASGEVY) | Sickle Cell Disease | Approved |
| VX-548 | Acute Pain | Phase 3 |
| VX-880 / VP-102 | Type 1 Diabetes | Phase 1/2 |
| VX-407 | Alpha-1 Antitrypsin Deficiency | Phase 2 |
| VX-670 | APOL1-Mediated Kidney Disease | Phase 2 |
| VX-522 | Cystic Fibrosis | Phase 1/2 |
Leadership Team at Vertex Pharmaceuticals
RK
Reshma Kewalramani
Chief Executive Officer and President
CW
Charles W. Wagner, Jr.
Executive Vice President and Chief Financial Officer
DA
David Altshuler
Executive Vice President, Global Research and Chief Scientific Officer
SA
Stuart A. Arbuckle
Executive Vice President and Chief Operating Officer
CB
Carmen Bozic
Executive Vice President, Global Medicines Development and Medical Affairs